{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:09:07Z","timestamp":1775614147757,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68872-z","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:15:48Z","timestamp":1722485748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["No difference in oncological outcomes and perioperative complications between patients with ESRD with unilateral and bilateral UTUC receiving radical nephroureterectomy"],"prefix":"10.1038","volume":"14","author":[{"given":"Tsu-Chen","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Heng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Chung","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Lung","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chou","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wun-Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hsiu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"See-Tong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-4302","authenticated-orcid":false,"given":"Po-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"1","key":"68872_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.semvascsurg.2021.02.010","volume":"34","author":"R Gupta","year":"2021","unstructured":"Gupta, R. et al. Epidemiology of end-stage kidney disease. Semin. Vasc. Surg. 34(1), 71\u201378 (2021).","journal-title":"Semin. Vasc. Surg."},{"issue":"2","key":"68872_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000514550","volume":"52","author":"JS Thurlow","year":"2021","unstructured":"Thurlow, J. S. et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 52(2), 98\u2013107 (2021).","journal-title":"Am. J. Nephrol."},{"key":"68872_CR3","volume":"2014","author":"S-M Wang","year":"2014","unstructured":"Wang, S.-M. et al. Increased upper and lower tract urothelial carcinoma in patients with end-stage renal disease: A nationwide cohort study in Taiwan during 1997\u20132008. BioMed Res. Int. 2014, 149750 (2014).","journal-title":"BioMed Res. Int."},{"issue":"1","key":"68872_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jfma.2013.10.022","volume":"114","author":"SM Wang","year":"2015","unstructured":"Wang, S. M. et al. Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease. J. Formos. Med. Assoc. 114(1), 52\u201357 (2015).","journal-title":"J. Formos. Med. Assoc."},{"issue":"8","key":"68872_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/cncr.22557","volume":"109","author":"CH Chang","year":"2007","unstructured":"Chang, C. H. et al. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 109(8), 1487\u20131492 (2007).","journal-title":"Cancer"},{"issue":"Suppl 1","key":"68872_CR6","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jfma.2021.12.013","volume":"121","author":"TS Lai","year":"2022","unstructured":"Lai, T. S. et al. Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010\u20132018. J. Formos. Med. Assoc. 121(Suppl 1), S5-s11 (2022).","journal-title":"J. Formos. Med. Assoc."},{"issue":"Suppl 1","key":"68872_CR7","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jfma.2021.12.015","volume":"121","author":"BS Wu","year":"2022","unstructured":"Wu, B. S. et al. Mortality rate of end-stage kidney disease patients in Taiwan. J. Formos. Med. Assoc. 121(Suppl 1), S12-s19 (2022).","journal-title":"J. Formos. Med. Assoc."},{"issue":"3","key":"68872_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria, F. et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J. Urol. 35(3), 379\u2013387 (2017).","journal-title":"World J. Urol."},{"key":"68872_CR9","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"issue":"7","key":"68872_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1442-2042.2006.01429.x","volume":"13","author":"PC Huang","year":"2006","unstructured":"Huang, P. C. et al. High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan. Int. J. Urol. 13(7), 864\u2013869 (2006).","journal-title":"Int. J. Urol."},{"issue":"12","key":"68872_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin. Drug Metab. Toxicol. 17(12), 1455\u20131466 (2021).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"68872_CR12","first-page":"66","volume":"6","author":"A Rizzo","year":"2024","unstructured":"Rizzo, A. et al. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project. Clin. Exp. Metastasis. 6, 66 (2024).","journal-title":"Clin. Exp. Metastasis."},{"issue":"1","key":"68872_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","volume":"8","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. et al. Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: A systematic review and meta-analysis. Eur. Urol. Focus 8(1), 152\u2013159 (2022).","journal-title":"Eur. Urol. Focus"},{"issue":"10","key":"68872_CR14","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin, T. K. et al. Prognostic significance of the Royal Marsden Hospital (RMH) Score in patients with cancer: A systematic review and meta-analysis. Cancers 16(10), 1835 (2024).","journal-title":"Cancers"},{"key":"68872_CR15","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven, D. C. et al. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Mol. Biosci. 9, 1039121 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"68872_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/s21020544","volume":"21","author":"YS Jeong","year":"2021","unstructured":"Jeong, Y. S. et al. Prediction of postoperative complications for patients of end stage renal disease. Sensors 21(2), 66 (2021).","journal-title":"Sensors"},{"issue":"13","key":"68872_CR17","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go, A. S. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296\u20131305 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"45","key":"68872_CR18","doi-asserted-by":"publisher","first-page":"79876","DOI":"10.18632\/oncotarget.20180","volume":"8","author":"CE Huang","year":"2017","unstructured":"Huang, C. E. et al. Nephroureterectomy increase 5 year survival in patients on dialysis with upper urinary tract urothelial carcinoma. Oncotarget 8(45), 79876\u201379883 (2017).","journal-title":"Oncotarget"},{"issue":"6","key":"68872_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cancers12061449","volume":"12","author":"V Mollica","year":"2020","unstructured":"Mollica, V. et al. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma. Cancers 12(6), 1449 (2020).","journal-title":"Cancers"},{"key":"68872_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.critrevonc.2024.104321","volume":"196","author":"FSM Monteiro","year":"2024","unstructured":"Monteiro, F. S. M. et al. Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis. Crit. Rev. Oncol. Hematol. 196, 104\u2013321 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"68872_CR21","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00262-023-03469-5","volume":"72","author":"M Santoni","year":"2023","unstructured":"Santoni, M. et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: The ARON-2 study. Cancer Immunol. Immunother. 72(9), 2961\u20132970 (2023).","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"68872_CR22","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1007\/s00262-023-03518-z","volume":"72","author":"O Fiala","year":"2023","unstructured":"Fiala, O. et al. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: Data from the ARON-2 retrospective study. Cancer Immunol. Immunother. 72(11), 3665\u20133682 (2023).","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"68872_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/diagnostics11111966","volume":"11","author":"YC Huang","year":"2021","unstructured":"Huang, Y. C. et al. Treatment strategy for dialysis patient with urothelial carcinoma. Diagnostics 11(11), 66 (2021).","journal-title":"Diagnostics"},{"key":"68872_CR24","doi-asserted-by":"publisher","first-page":"175628722311717","DOI":"10.1177\/17562872231171757","volume":"15","author":"M Zein","year":"2023","unstructured":"Zein, M. et al. Concurrent radical cystectomy and nephroureterectomy indications and outcomes: A systematic review and comparative analysis. Ther. Adv. Urol. 15, 17562872231171756 (2023).","journal-title":"Ther. Adv. Urol."},{"issue":"2","key":"68872_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1245\/s10434-017-6251-2","volume":"25","author":"YC Huang","year":"2018","unstructured":"Huang, Y. C. et al. Perioperative complications and mortality in patients with urothelial carcinoma and end-stage renal disease undergoing one-stage complete urinary tract extirpation. Ann. Surg. Oncol. 25(2), 573\u2013581 (2018).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"68872_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.ju.0000101758.41635.28","volume":"171","author":"CF Wu","year":"2004","unstructured":"Wu, C. F. et al. Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma. J. Urol. 171(1), 126\u2013129 (2004).","journal-title":"J. Urol."},{"issue":"2","key":"68872_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1440-1797.2010.01366.x","volume":"16","author":"TY Wang","year":"2011","unstructured":"Wang, T. Y. et al. High incidence and recurrence of transitional cell carcinoma in Taiwanese patients with end-stage renal disease. Nephrology 16(2), 225\u2013231 (2011).","journal-title":"Nephrology"},{"issue":"4","key":"68872_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-011-9960-7","volume":"43","author":"SF Tseng","year":"2011","unstructured":"Tseng, S. F. et al. Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. Int. Urol. Nephrol. 43(4), 1067\u20131071 (2011).","journal-title":"Int. Urol. Nephrol."},{"issue":"4","key":"68872_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.21037\/tau.2019.12.25","volume":"9","author":"A Levy","year":"2020","unstructured":"Levy, A. et al. Perioperative complications and adverse sequelae of radical nephroureterectomy. Transl. Androl. Urol. 9(4), 1853\u20131859 (2020).","journal-title":"Transl. Androl. Urol."},{"issue":"4","key":"68872_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11255-017-1522-1","volume":"49","author":"CH Ou","year":"2017","unstructured":"Ou, C. H. et al. Long-term outcomes of complete urinary tract exenteration for dialysis patients with urothelial cancer. Int. Urol. Nephrol. 49(4), 623\u2013627 (2017).","journal-title":"Int. Urol. Nephrol."},{"key":"68872_CR31","doi-asserted-by":"publisher","first-page":"117955492110355","DOI":"10.1177\/11795549211035541","volume":"15","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Bilateral nephroureterectomy versus unilateral nephroureterectomy for treating de novo upper tract urothelial carcinoma after renal transplantation: A comparison of surgical and oncological outcomes. Clin. Med. Insights Oncol. 15, 11795549211035540 (2021).","journal-title":"Clin. Med. Insights Oncol."},{"issue":"1","key":"68872_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","volume":"62","author":"G Lughezzani","year":"2012","unstructured":"Lughezzani, G. et al. Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur. Urol. 62(1), 100\u2013114 (2012).","journal-title":"Eur. Urol."},{"issue":"3","key":"68872_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00345-016-1826-2","volume":"35","author":"A Mbeutcha","year":"2017","unstructured":"Mbeutcha, A. et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: A systematic review. World J. Urol. 35(3), 337\u2013353 (2017).","journal-title":"World J. Urol."},{"issue":"2","key":"68872_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MAJ.0b013e318223e800","volume":"342","author":"PH Hung","year":"2011","unstructured":"Hung, P. H. et al. Urothelial carcinoma in patients with advanced kidney disease: A 12-year retrospective cohort survey. Am. J. Med. Sci. 342(2), 148\u2013152 (2011).","journal-title":"Am. J. Med. Sci."},{"issue":"6","key":"68872_CR35","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.eururo.2009.12.029","volume":"57","author":"G Novara","year":"2010","unstructured":"Novara, G. et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: An international validation study. Eur. Urol. 57(6), 1064\u20131071 (2010).","journal-title":"Eur. Urol."},{"issue":"12","key":"68872_CR36","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1016\/j.ejca.2013.04.016","volume":"49","author":"JH Ku","year":"2013","unstructured":"Ku, J. H. et al. Lymphovascular invasion as a prognostic factor in the upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Eur. J. Cancer 49(12), 2665\u20132680 (2013).","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"68872_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033485","volume":"102","author":"YL Chang","year":"2023","unstructured":"Chang, Y. L. et al. The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis. Medicine 102(15), e33485 (2023).","journal-title":"Medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68872-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:16:09Z","timestamp":1722485769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68872-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68872"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68872-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17766"}}